- Conditions
- Anesthesia, Pain
- Interventions
- Ketorolac Tromethamine, Hydromorphone, Ketamine, Oxycodone, Morphine, Fentanyl (IV)
- Drug
- Lead sponsor
- Chi Dang Hornik
- Other
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 551 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 11
- States / cities
- Stanford, California • Aurora, Colorado • Wilmington, Delaware + 7 more
Location Directory
Clinical trials in Aurora, Colorado
This page shows live ClinicalTrials.gov search results for Aurora, Colorado, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
7450
Shown on this page
12
Current sort
Recently updated
Location scope
Aurora, CO
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 721–732 of 7,450 matching trials in Aurora, CO.
Live ClinicalTrials.gov results.
Institutions in Aurora
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Hypertension, Cardiovascular Diseases, Vascular Diseases
- Interventions
- Paradise Ultrasound Renal Denervation Treatment
- Device
- Lead sponsor
- ReCor Medical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 46
- States / cities
- Long Beach, California • Los Angeles, California • Sacramento, California + 39 more
- Conditions
- Small-cell Lung Cancer
- Interventions
- ZL-1310, Investigator's Choice of Therapy
- Drug
- Lead sponsor
- Zai Lab (Shanghai) Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 37
- States / cities
- La Jolla, California • Sacramento, California • Aurora, Colorado + 30 more
- Conditions
- Patient-Reported Outcome Measures (PROMs), Pragmatic Trial, Adolescent Congenital Heart Disease, Resiliency-building Intervention, Resilience, Psychological, Telemedicine-Based Education
- Interventions
- Telemedicine-based resiliency-building intervention
- Behavioral
- Lead sponsor
- Carelon Research
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 390 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 14
- States / cities
- Stanford, California • Aurora, Colorado • Atlanta, Georgia + 10 more
- Conditions
- Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
- Interventions
- Gemcitabine Hydrochloride, Cisplatin, Pegfilgrastim, Conventional Surgery, Radical Cystectomy, Chemoradiotherapy
- Drug · Biological · Procedure + 1 more
- Lead sponsor
- Alliance for Clinical Trials in Oncology
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 237 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2030
- U.S. locations
- 424
- States / cities
- Fairbanks, Alaska • Goodyear, Arizona • Phoenix, Arizona + 293 more
- Conditions
- Gram-negative Bacterial Infection
- Interventions
- Part A: ATM-AVI Single Dose, Cohorts 1-4, Part B: Multiple-dose ATM-AVI, Cohorts 1-4
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- Up to 39 Weeks
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 11
- States / cities
- Orange, California • Aurora, Colorado • Indianapolis, Indiana + 4 more
- Conditions
- Chronic Graft-versus-host-disease
- Interventions
- Axatilimab, Ruxolitinib, Corticosteroids
- Drug
- Lead sponsor
- Incyte Corporation
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Duarte, California • Los Angeles, California + 18 more
- Conditions
- Recurrent Glioma, Recurrent WHO Grade 2 Glioma, Recurrent WHO Grade 3 Glioma, Recurrent WHO Grade 4 Glioma
- Interventions
- Biospecimen Collection, Erdafitinib, Magnetic Resonance Imaging, Optical Coherence Tomography
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 27
- States / cities
- Aurora, Colorado • Coral Gables, Florida • Deerfield Beach, Florida + 19 more
- Conditions
- Breast Cancer
- Interventions
- Palbociclib, Fulvestrant, Adjuvant Therapy
- Drug
- Lead sponsor
- Criterium, Inc.
- Industry
- Eligibility
- Not listed
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2028
- U.S. locations
- 19
- States / cities
- Tucson, Arizona • Los Angeles, California • Aurora, Colorado + 15 more
- Conditions
- Cow's Milk Allergy
- Interventions
- Experimental Extensively Hydrolyzed Formula, Placebo Extensively Hydrolyzed Formula
- Other
- Lead sponsor
- Abbott Nutrition
- Industry
- Eligibility
- 3 Months to 12 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Chicago, Illinois + 6 more
- Conditions
- Facioscapulohumeral Muscular Dystrophy (FSHD)
- Interventions
- Placebo, RO7204239
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 4
- States / cities
- Orange, California • Aurora, Colorado • Fairway, Kansas + 1 more
- Conditions
- Severe Alopecia Areata
- Interventions
- Ritlecitinib higher dose, Ritlecitinib lower dose
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 6 Years to 14 Years
- Enrollment
- 140 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 23
- States / cities
- Irvine, California • Santa Ana, California • Aurora, Colorado + 17 more